(PQD2) Why is Endemic Burkitt Lymphoma Curable with Single Agent Chemotherapy?
(PQD2) Why is Endemic Burkitt Lymphoma Curable with Single Agent Chemotherapy?
批准号:
8720728
负责人:
Dirk P Dittmer
金额:
$19.24万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-01 至 2016-08-31
关键词:
AddressAfrican Burkitt&aposs lymphomaAnimal ModelApoptosisBCL2 geneBiochemicalBiological ModelsBrazilBurkitt LymphomaCell LineCellsChildCombination Drug TherapyCyclophosphamideDNADNA DamageDataDevelopmentDoxorubicinDrug resistanceEtoposideFailureFrequenciesG1 ArrestGenesGeneticGenetic TranscriptionGenomeGoalsHeterogeneityHuman Herpesvirus 4KnowledgeLeadLymphomaMalignant NeoplasmsModelingMolecularMolecular BiologyMusMutationNatureNormal CellPathway interactionsPatientsPerformancePharmaceutical PreparationsPhasePropertyPublicationsRegimenRelapseResistanceSmall Interfering RNAStructure of germinal center of lymph nodeSystemTestingTimeUgandaValidationViralchemosensitizing agentchemotherapycytotoxicexomehigh throughput screeningin vivo Modelknock-downlarge cell Diffuse non-Hodgkin&aposs lymphomamouse modelneoplastic cellnovelprogramspublic health relevancerepairedresistance mutationresponsescreeningsocioeconomicstumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This application is in response to RFA-CA12-022. It addresses PQD - 2 what molecular properties make some cancers curable with conventional chemotherapy? We choose EBV+ endemic Burkitt lymphoma (BL) as the prototypical cancer that is curable with single agent (cyclophosphamide) in >90% of children. This exceedingly high cure rate was already evident in the 1960s in very limited settings (Uganda) and has since been repeated in the US, in Brazil and other nations. Failure is due to co-factors, including socioeconomically and over all performance score, which limit the patients to complete the prescribed number of cycles, rather than molecular heterogeneity. Hence, the reason that this very aggressive cancer is curable is molecular in nature. We will use a functional genetic approach to understand the molecular properties that render BL susceptible to one of the simplest of chemotherapies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PQ6: Transgenic Mouse Model for Kaposi Sarcoma
-
批准号:10334549
-
项目类别:
-
资助金额:$51.54万
-
财政年份:2020
-
负责人:Dirk P Dittmer
-
依托单位:
Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa
-
批准号:10434864
-
项目类别:
-
资助金额:$18.45万
-
财政年份:2020
-
负责人:Dirk P Dittmer
-
依托单位:
Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa
-
批准号:10652401
-
项目类别:
-
资助金额:$18.45万
-
财政年份:2020
-
负责人:Dirk P Dittmer
-
依托单位:
Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa
-
批准号:10084558
-
项目类别:
-
资助金额:$21.23万
-
财政年份:2020
-
负责人:Dirk P Dittmer
-
依托单位:
PQ6: Transgenic Mouse Model for Kaposi Sarcoma
-
批准号:10115683
-
项目类别:
-
资助金额:$52.16万
-
财政年份:2020
-
负责人:Dirk P Dittmer
-
依托单位:
Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa
-
批准号:10238161
-
项目类别:
-
资助金额:$18.45万
-
财政年份:2020
-
负责人:Dirk P Dittmer
-
依托单位:
PQ6: Transgenic Mouse Model for Kaposi Sarcoma
-
批准号:10579826
-
项目类别:
-
资助金额:$50.76万
-
财政年份:2020
-
负责人:Dirk P Dittmer
-
依托单位:
Planning for a National Non-Communicable Disease Center of Research Excellence
-
批准号:9337384
-
项目类别:
-
资助金额:$25.18万
-
财政年份:2016
-
负责人:Dirk P Dittmer
-
依托单位:
Planning for a National Non-Communicable Disease Center of Research Excellence
-
批准号:9193832
-
项目类别:
-
资助金额:$26.48万
-
财政年份:2016
-
负责人:Dirk P Dittmer
-
依托单位:
Origin and Lineage of Differentiation of Kaposi's Sarcoma
-
批准号:8839925
-
项目类别:
-
资助金额:$17.29万
-
财政年份:2015
-
负责人:Dirk P Dittmer
-
依托单位:
HIV and substances of abuse influence exosomes and endothelial cell function
-
批准号:9304176
-
项目类别:
-
资助金额:$37.05万
-
财政年份:2015
-
负责人:Dirk P Dittmer
-
依托单位:
Origin and Lineage of Differentiation of Kaposi's Sarcoma
-
批准号:9109595
-
项目类别:
-
资助金额:$17.33万
-
财政年份:2015
-
负责人:Dirk P Dittmer
-
依托单位:
HIV and substances of abuse influence exosomes and endothelial cell function
-
批准号:8987274
-
项目类别:
-
资助金额:$39.2万
-
财政年份:2015
-
负责人:Dirk P Dittmer
-
依托单位:
(PQD2) Why is Endemic Burkitt Lymphoma Curable with Single Agent Chemotherapy?
-
批准号:8590757
-
项目类别:
-
资助金额:$16.53万
-
财政年份:2013
-
负责人:Dirk P Dittmer
-
依托单位:
ART Modulation of Viral Pathogenesis
-
批准号:10380053
-
项目类别:
-
资助金额:$36.93万
-
财政年份:2007
-
负责人:Dirk P Dittmer
-
依托单位:
ART Modulation of Viral Pathogenesis in Oral Epithelia
-
批准号:8064006
-
项目类别:
-
资助金额:$30.51万
-
财政年份:2007
-
负责人:Dirk P Dittmer
-
依托单位:
ART Modulation of Viral Pathogenesis in Oral Epithelia
-
批准号:7835669
-
项目类别:
-
资助金额:$31.45万
-
财政年份:2007
-
负责人:Dirk P Dittmer
-
依托单位:
ART Modulation of Viral Pathogenesis
-
批准号:10609801
-
项目类别:
-
资助金额:$36.93万
-
财政年份:2007
-
负责人:Dirk P Dittmer
-
依托单位:
ART Modulation of Viral Pathogenesis
-
批准号:8734371
-
项目类别:
-
资助金额:$37.78万
-
财政年份:2007
-
负责人:Dirk P Dittmer
-
依托单位:
ART Modulation of Viral Pathogenesis in Oral Epithelia
-
批准号:7609198
-
项目类别:
-
资助金额:$31.77万
-
财政年份:2007
-
负责人:Dirk P Dittmer
-
依托单位: